
Vaccines, Biologics: Indian Pharma’s New Temptations
API, diagnostics, New Chemical Entity — Covid has thrown up new opportunities, and domestic pharma biggies are charging in with renewed focus.
API, diagnostics, New Chemical Entity — Covid has thrown up new opportunities, and domestic pharma biggies are charging in with renewed focus.
In the coming year, the pharma industry will continue to reimagine itself while driving growth and boosting value.
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Restructuring to simplify corporate structure, create two separate listed entities.
In the latest episode of Biz Buzz, Umang Vohra, global MD & CEO, Cipla, talks about the paradigm shift in the Indian pharma industry, and Cipla's plans for booster shots of Covid-19 vaccine.
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
The production-linked incentive schemes seek to reimagine the dreams of the Indian economy. It will, of course, take a few years to completely evaluate the impact of them.
The healthcare sector is dominated by family-run firms, some of which have come into prominence in the past year.
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.